logo
logo
Sign in

Cardiovascular Therapy Market Research 2020-2025 Report by Share, Trend, Global Industry Size, Price, Future Analysis

avatar
Rahul Sharma
Cardiovascular Therapy Market Research 2020-2025 Report by Share, Trend, Global Industry Size, Price, Future Analysis

Cardiovascular Therapy Market pertain to the blood vessel and heart conditions that can affect the heart valve, cardiac muscle with the circulation system that monitors the blood flow and distribution and the cardiac electrical system which controls the heart rhythm and rate. These complex systems are taken care of by the cardiovascular therapy device market owing to the increasing number of global population being affected by the above mentioned diseases. The cardiovascular therapy market is expected to grow in the forecast period owing to introduction of improved technologies and devices that provide solutions for Cardio vascular diseases.

 

Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market/request-sample

 

The key driving factors responsible for the growth of Cardiovascular Therapy market :

 

Growth in the global cardiovascular therapy market is attributed to factors owing to increasing worldwide prevalence of chronic CVDs and a higher percentage of aging population. Improvements in treatment capabilities in developing markets owing to technological advancements and innovation is expected to have a positive impact on the demand for cardiovascular thereupatic devices in the medical and healthcare sector. Technological advent with respect to therapeutic devices includes development of extended product life, smaller devices, and surgical improvements. Increase in demand is also driven by increased risk factors (diabetes, smoking, obesity, and hypertension) among people

 

Key application of in cardiovascular therapy is the hybrid operation rooms market that emphasizes on minimal invasive surgeries. Therefore, Global cardiovascular therapy market is expected to witness a growth owing to increasing demand for minimally invasive surgeries. However, high costs for treatment and safety concerns are major challenges before the market.  Cardiovascular therapy comprises of Anti-hypertensives, anticoagulants, anti-arrhythmic, Antithrombotics and Antidyslipidemics. Global cardiovascular market had a sale of $170bn in 2010 and is expected to have a positive growth in the forecast period. With a share of 40% of the total market, the US continued to be the market leader in this segment. Although there has been a decline in the sales of cardiovascular therapy market due to saturation of key drug categories and an increased generic presence, the US witnessed a steady growth in the market since 2009 and is expected to continue the same trend.

 

Antihypertensives remained the largest drug class in the past few years with global sales of over $37.6bn and an overall market share of over 22%. Angiotensin receptor blockers (ARBs) is expected to remain the most prescribed therapeutic class within antihypertensives driven by key brands such as Cozaar, Diovan, and Avapro. Novartis’s Diovan is the market leader with $3.6bn in sales and the second largest being Benicar with sales of $2.9bn.  The anticoagulants segment is expected to witness significant activity over the forecast period owing to introduction of new drugs such as BoehringerPradaxa/Rendix, Ingelheim's, Bayer-Schering/J&J's, BMS/Pfizer's apixaban, Xarelto and Eli Lilly/Daiichi's Effient which are subjected to intensive R&D activities. Since most of the factor Xa inhibitors are in oral form, they are expected to cater to a wider market.

 

Crestor is expected to witness a steady growth in the market owing to positive trial results that has the capability to strengthen its market position. The positive trial data is likely to result in higher number of recommendations for cholesterol treatment and capture more number of patients with cardiovascular disorders GlaxoSmithKline's (GSK) is expected to have the highest growth among leading players owing to the acquisition of Reliant Pharma. Addition of new drugs such as Lovaza in GSKs portfolio is a key factor that can drive the growth in this segment  In 2010, Antithrombotics recorded a sale of over $18.7bn and a market share of over 11%. Antithrombitics are forecasted to witness a strong growth in the next seven years owing to increase in the commercialization of recently approved products such as Xarelto, Pradaxa and launch of Pfizer/BMS’s apixabanBetter bleeding profile and superior effectiveness of Brilinta (ticagrelor) over Plavix make it major antithrombotic drug that could be a key player in acute coronary syndrome (ACS).

 

View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market

collect
0
avatar
Rahul Sharma
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more